Skip to main content
AAN.com
Brief Communications
June 13, 2000

Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor

June 13, 2000 issue
54 (11) 2147-2150

Abstract

Article abstract Four of 10 patients who were enrolled on protocols of high-dose immunosuppression with peripheral blood stem cell rescue for MS experienced neurologic worsening while receiving recombinant human granulocyte colony-stimulating factor. There was improvement when methylprednisolone was given to three of the patients, but one patient died of respiratory failure. The mechanism of the neurologic worsening is uncertain.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Burt RK, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998;92:3505–3514.
2.
Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 1997;24:2153–2157.
3.
Mielcarek M, Martin PJ, Torok-Storb B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 1997;89:1629–1634.
4.
Kusnierz-Glaz CR, Still BJ, Amano M, et al. Granulocyte colony-stimulating factor-induced co-mobilization of CD4 CD8 T cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors. Blood 1997;89:2586–2595.
5.
Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems, and perspectives. Brain 1997;120:865–916.
6.
Hartung T, Docke WD, Gantner F, et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995;85:2482–2489.
7.
Pan L, Delmonte J Jr, Jalonen CK, Ferrara JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422–4429.
8.
Xu S, Hoglund M, Venge P. The effect of granulocyte colony-stimulating factor (G-CSF) on the degranulation of secondary granule proteins from human neutrophils in vivo may be indirect. Br J Haematol 1996;93:558–568.
9.
Lee CK, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant 1995;16:175–182.
10.
Crockard AD, Boylan MT, Droogan AG, McMillan SA, Hawkins SA. Methylprednisolone-induced neutrophil leukocytosis down-modulation of neutrophil L-selectin and Mac-1 expression and induction of granulocyte-colony stimulating factor. Int J Clin Lab Res 1998;28:110–115.

Information & Authors

Information

Published In

Neurology®
Volume 54Number 11June 13, 2000
Pages: 2147-2150
PubMed: 10851379

Publication History

Received: January 20, 2000
Accepted: February 10, 2000
Published online: June 13, 2000
Published in print: June 13, 2000

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

H. Openshaw, MD
From the Department of Neurology (Dr. Openshaw) and Division of Hematology and Bone Marrow Transplantation (Drs. Kashyap and Forman)City of Hope National Medical Center, Duarte, CA; the Departments of Neurology (Dr. Stuve) and Medical Oncology (Drs. Nash and McSweeney), Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle; the Neuroimmunology Unit (Dr. Antel), Montreal Neurological Institute, McGill University, Montreal, Canada; and the Department of Neurology (Drs. Lund and Weiner), University of Southern California School of Medicine, Los Angeles.
O. Stuve, MD
From the Department of Neurology (Dr. Openshaw) and Division of Hematology and Bone Marrow Transplantation (Drs. Kashyap and Forman)City of Hope National Medical Center, Duarte, CA; the Departments of Neurology (Dr. Stuve) and Medical Oncology (Drs. Nash and McSweeney), Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle; the Neuroimmunology Unit (Dr. Antel), Montreal Neurological Institute, McGill University, Montreal, Canada; and the Department of Neurology (Drs. Lund and Weiner), University of Southern California School of Medicine, Los Angeles.
J.P. Antel, MD
From the Department of Neurology (Dr. Openshaw) and Division of Hematology and Bone Marrow Transplantation (Drs. Kashyap and Forman)City of Hope National Medical Center, Duarte, CA; the Departments of Neurology (Dr. Stuve) and Medical Oncology (Drs. Nash and McSweeney), Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle; the Neuroimmunology Unit (Dr. Antel), Montreal Neurological Institute, McGill University, Montreal, Canada; and the Department of Neurology (Drs. Lund and Weiner), University of Southern California School of Medicine, Los Angeles.
R. Nash, MD
From the Department of Neurology (Dr. Openshaw) and Division of Hematology and Bone Marrow Transplantation (Drs. Kashyap and Forman)City of Hope National Medical Center, Duarte, CA; the Departments of Neurology (Dr. Stuve) and Medical Oncology (Drs. Nash and McSweeney), Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle; the Neuroimmunology Unit (Dr. Antel), Montreal Neurological Institute, McGill University, Montreal, Canada; and the Department of Neurology (Drs. Lund and Weiner), University of Southern California School of Medicine, Los Angeles.
B.T. Lund, PhD
From the Department of Neurology (Dr. Openshaw) and Division of Hematology and Bone Marrow Transplantation (Drs. Kashyap and Forman)City of Hope National Medical Center, Duarte, CA; the Departments of Neurology (Dr. Stuve) and Medical Oncology (Drs. Nash and McSweeney), Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle; the Neuroimmunology Unit (Dr. Antel), Montreal Neurological Institute, McGill University, Montreal, Canada; and the Department of Neurology (Drs. Lund and Weiner), University of Southern California School of Medicine, Los Angeles.
L.P. Weiner, MD
From the Department of Neurology (Dr. Openshaw) and Division of Hematology and Bone Marrow Transplantation (Drs. Kashyap and Forman)City of Hope National Medical Center, Duarte, CA; the Departments of Neurology (Dr. Stuve) and Medical Oncology (Drs. Nash and McSweeney), Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle; the Neuroimmunology Unit (Dr. Antel), Montreal Neurological Institute, McGill University, Montreal, Canada; and the Department of Neurology (Drs. Lund and Weiner), University of Southern California School of Medicine, Los Angeles.
A. Kashyap, MD
From the Department of Neurology (Dr. Openshaw) and Division of Hematology and Bone Marrow Transplantation (Drs. Kashyap and Forman)City of Hope National Medical Center, Duarte, CA; the Departments of Neurology (Dr. Stuve) and Medical Oncology (Drs. Nash and McSweeney), Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle; the Neuroimmunology Unit (Dr. Antel), Montreal Neurological Institute, McGill University, Montreal, Canada; and the Department of Neurology (Drs. Lund and Weiner), University of Southern California School of Medicine, Los Angeles.
P. McSweeney, MD
From the Department of Neurology (Dr. Openshaw) and Division of Hematology and Bone Marrow Transplantation (Drs. Kashyap and Forman)City of Hope National Medical Center, Duarte, CA; the Departments of Neurology (Dr. Stuve) and Medical Oncology (Drs. Nash and McSweeney), Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle; the Neuroimmunology Unit (Dr. Antel), Montreal Neurological Institute, McGill University, Montreal, Canada; and the Department of Neurology (Drs. Lund and Weiner), University of Southern California School of Medicine, Los Angeles.
S. Forman, MD
From the Department of Neurology (Dr. Openshaw) and Division of Hematology and Bone Marrow Transplantation (Drs. Kashyap and Forman)City of Hope National Medical Center, Duarte, CA; the Departments of Neurology (Dr. Stuve) and Medical Oncology (Drs. Nash and McSweeney), Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle; the Neuroimmunology Unit (Dr. Antel), Montreal Neurological Institute, McGill University, Montreal, Canada; and the Department of Neurology (Drs. Lund and Weiner), University of Southern California School of Medicine, Los Angeles.

Notes

Address correspondence and reprint requests to Dr. Harry Openshaw, Department of Neurology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Cytokine Profiling in Cerebrospinal Fluid of Patients with Newly Diagnosed Relapsing-Remitting Multiple Sclerosis (RRMS): Associations between Inflammatory Biomarkers and Disease Activity, International Journal of Molecular Sciences, 25, 13, (7399), (2024).https://doi.org/10.3390/ijms25137399
    Crossref
  2. Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim, Blood Advances, 8, 15, (4196-4206), (2024).https://doi.org/10.1182/bloodadvances.2024012646
    Crossref
  3. Neutropaenia complications from Ocrelizumab and Rituximab treatment, Multiple Sclerosis and Related Disorders, 81, (105147), (2024).https://doi.org/10.1016/j.msard.2023.105147
    Crossref
  4. Hematopoietic stem cell transplantation for multiple sclerosis, Hematopoietic Stem Cell Transplantation for Neurologic Diseases, (153-167), (2024).https://doi.org/10.1016/B978-0-323-90242-7.00011-0
    Crossref
  5. The HSCT procedure (I): Mobilization, collection, manipulation, and cryopreservation of a HSC graft, Hematopoietic Stem Cell Transplantation for Neurologic Diseases, (105-115), (2024).https://doi.org/10.1016/B978-0-323-90242-7.00005-5
    Crossref
  6. B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease, Current Neurology and Neuroscience Reports, 24, 10, (479-494), (2024).https://doi.org/10.1007/s11910-024-01366-7
    Crossref
  7. Autogreffe de cellules souches hématopoïétiques en neurologie inflammatoire, Pratique Neurologique - FMC, 14, 1, (65-70), (2023).https://doi.org/10.1016/j.praneu.2023.01.007
    Crossref
  8. Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab, Neurología (English Edition), 38, 7, (463-466), (2023).https://doi.org/10.1016/j.nrleng.2021.01.005
    Crossref
  9. Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab, Neurología, 38, 7, (463-466), (2023).https://doi.org/10.1016/j.nrl.2021.01.010
    Crossref
  10. Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis, Rheumatology, 62, SI, (SI107-SI113), (2022).https://doi.org/10.1093/rheumatology/keac455
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share